Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo
Schwab C, Roque D, English D, Bellone S, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D, Azodi M, Schwartz P, Rutherford T, Santin A. Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. Gynecologic Oncology 2015, 136: 397-398. DOI: 10.1016/j.ygyno.2014.11.032.Peer-Reviewed Original ResearchIrreversible ErbB family blockerErbB family blockerSerous endometrial cancerEndometrial cancerAfatinibBlockersHER2Cancer